Research status of radiotherapy combined with EGFR-TKI for brain metastases in patients with EGFR-mutant NSCLC
Xiang Xing, Yang Wengang, Chen Xiaxia, Geng Yichao, Ma Zhu, Su Shengfa, Ouyang Weiwei, Lu Bing
Department of Oncology, Clinical College of Guizhou Medical University, Affiliated Hospital of Guizhou Medical University/Guizhou Provincial Cancer Hospital, Guiyang 550004, China
Abstract：The prognosis of patients with brain metastases from non-small cell lung cancer (NSCLC) is poor. Tyrosine kinase inhibitor (TKI) significantly improves the prognosis of patients with epidermal growth factor receptor (EGFR) sensitive mutation. EGFR sensitive mutations are associated with the incidence of brain metastases in NSCLC and may affect the efficacy of radiotherapy and TKI therapy. Both EGFR-TKI and radiotherapy are effective for EGFR-mutant NSCLC with brain metastases. Whether the combination of EGFR-TKI and radiotherapy may improve the prognosis compared with EGFR-TKI or radiotherapy alone has been studied. Retrospective studies have indicated that upfront radiotherapy, especially upfront stereotaxic radiosurgery combined with EGFR-TKI may be more advantageous in improving the prognosis, but it is still controversial. Therefore, clinical research progresses on the radiotherapy for EGFR-mutant NSCLC patients with brain metastases were reviewed.
Xiang Xing,Yang Wengang,Chen Xiaxia et al. Research status of radiotherapy combined with EGFR-TKI for brain metastases in patients with EGFR-mutant NSCLC[J]. Chinese Journal of Radiation Oncology, 2021, 30(6): 637-642.
[1] Wang W, Song Z, Zhang Y. Efficacy of brain radiotherapy plus EGFR-TKI for EGFR-mutated non-small cell lung cancer patients who develop brain metastasis[J]. Arch Med Sci, 2018, 14(6):1298-1307.DOI:105114/aoms.2018.78939. [2] Chung SY, Chang JH, Kim HR, et al. Optimal dose and volume for postoperative radiotherapy in brain oligometastases from lung cancer:a retrospective study[J]. Radiat Oncol J, 2017, 35(2):153-162. DOI: 10.3857/roj.2017.00094. [3] 曹建忠,李红卫. EGFR突变状态对NSCLC脑转移和放疗及靶向治疗疗效影响[J]. 中华放射肿瘤学杂志,2016, 25(3):296-300.DOI:10.3760/cma.j.issn.1004-4221.2016.03.023. Cao JZ, Li HW. The effect of brain metastases from NSCLC and treatment targeted plus radiotherapy on EGFR mutations[J]. Chin J Radiat Oncol, 2016, 25(3):296-300.DOI:10.3760/cma.j.issn.1004-4221.2016.03.023. [4] 孔玲玲,邢力刚. EGFR-TKI治疗非小细胞肺癌脑转移的研究进展[J]. 中华转移性肿瘤杂志, 2019, 002(002):45-49. DOI:10.3760/ cma.j.issn.2096-5400.2019.02.010. Kong LL, Xing LG, Current progress on clinical trials using EGFR-TKI therapy in NSCLC patients with brain metastasis[J]. Chin J Metast Cancer, 2019, 2(2):45-49. DOI:10.3760/ cma.j.issn.2096-5400.2019.02.010. [5] 刘麾, 苏胜发, 欧阳伟炜,等. Ⅲ-Ⅳ期NSCLC同期放化疗后失败模式及寡转移规律探讨[J]. 中华放射肿瘤学杂志, 2016, 25(1):20-24.DOI:10.3760/cma.j.issn.1004-4221.2016.01.006 Liu H, Su SF, Ouyang WW, et al. Failure patterns and oligometastasis after concurrent chemoradiotherapy for stage Ⅲ-Ⅳ non-small cell lung cancer[J]. Chin J Radiat Oncol, 2016, 25(1):20-24.DOI:10.3760/cma.j.issn.1004-4221.2016.01.006. [6] Chao S T, Barnett G H, Vogelbaum M A, et al. Salvage stereotactic radiosurgery effectively treats recurrences from whole brain radiation therapy[J]. Cancer, 2008, 113(8):2198-2204.DOI:10.1002/cncr.23821. [7] Kim KH, Lee J, Lee JI, et al. Can upfront systemic chemotherapy replace stereotactic radiosurgery or whole brain radiotherapy in the treatment of non-small cell lung cancer patients with asymptomatic brain metastases?[J]. Lung Cancer, 2010, 68(2):258-263.DOI:10.1016/j.lungcan. 2009. 06.008. [8] Scagliotti G, von Pawel J, Novello S, et al. Phase Ⅲ multinational, randomized, double-blind, placebo-controlled study of tivantinib (ARQ 197) plus erlotinib versus erlotinib alone in previously treated patients with locally advanced or metastatic nonsquamous non–small-cell lung cancer[J]. J Clin Oncol, 2015, 33(24):2667-2674.DOI:10.1200/JCO. 2014.60.7317. [9] Schuler M, Wu YL, Hirsh V, et al. First-line afatinib versus chemotherapy in patients with non–small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases[J]. J Thor Oncol, 2016, 11(3):380-390.DOI:10.1016/j.jtho.2015.11.014. [10] Romano R, Bucci C. Role of EGFR in the Nervous System[J]. Cells. 2020, 9(8):1887.DOI:10.3390/cells9081887. [11] Lee JH, Chen HY, Hsu FM, et al. Cranial irradiation for patients with epidermal growth factor receptor (EGFR) mutant lung cancer who have brain metastases in the era of a new generation of egfr inhibitors[J]. Oncologist, 2019, 24:e1417-e1425. DOI:10.1634/theoncologist.2019-0152. [12] Fujita Y, Kinoshita M, Ozaki T, et al. The impact of EGFR mutation status and single brain metastasis on the survival of non-small-cell lung cancer patients with brain metastases[J]. Neurooncol Adv, 2020, 2(1):vdaa064.DOI:10.1093/noajnl/vdaa064. [13] 陈丽敏,傅梦姣,周建娅,等. EGFR-TKIs联合伽玛刀治疗EGFR突变的肺腺癌伴脑转移的预后分析[J]. 中国肺癌杂志, 2019, 22(5):312-318. DOI:10.3779/j.issn.1009-3419.2019.05.08. Chen LM, Fu MJ, Zhou JY, et al. Prognostic analysis of EGFR-TKIs combined with Gamma knife in EGFR-mutant lung adenocarcinoma with brain metastasis[J]. Chin J Lung Cancer, 2019, 22(5):312-318. DOI:10.3779/j.issn.1009-3419.2019.05.08. [14] Yang H, He D, Wang F, et al. A study on different therapies and prognosis-related factors for brain metastases in lung adenocarcinoma patients with driver mutation[J]. Clin Exper Metast, 2020, 37(3):391-399. DOI:org/10.1007/s10585-020-10026-2. [15] Heon S, Yeap BY, Britt GJ, et al. Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib[J]. Clin Cancer Res, 2010, 16(23):5873-5882. DOI:10.1158/1078-0432. CCR-10-1588. [16] 郑裕,李仕红,林光武,等. 不同EGFR突变类型NSCLC脑转移的MRI影像特点[J]. 老年医学与保健, 2019, 25(2):190-195. DOI:10.3969/j.issn.1008-8296.2019.02.016. Zhen Y, Li SH, Lin GW, et al. MRI features of NSCLC brain metastasis with different egfr mutation[J]. Geriatr Health Care, 2019, 25(2):190-195. DOI:CNKI:10.3969/j.issn.1008-8296.2019.02.016. [17] Wu YL, Zhou C, Cheng Y, et al. Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases:a phase Ⅱ study (CTONG-0803)[J]. Ann Oncol, 2013, 24(4):993-999. DOI:10.1093/annonc/mds529. [18] Liu Y, Deng L, Zhou X, et al. Concurrent brain radiotherapy and EGFR-TKI may improve intracranial metastases control in non-small cell lung cancer and have survival benefit in patients with low DS-GPA score[J]. Oncotarget, 2017, 8(67):111309-111317.DOI:10.18632/oncotarget.22785. [19] He ZY, Li MF, Lin JH, et al. Comparing the efficacy of concurrent EGFR-TKI and whole-brain radiotherapy vs. EGFR-TKI alone as a first-line therapy for advanced EGFR-mutated non-small-cell lung cancer with brain metastases:a retrospective cohort study[J]. Cancer Manag Res, 2019, 11:2129-2138. DOI:10.2147/CMAR. S184922. [20] Chen C, Wu Y, Liu BL, et al. Whole-brain radiotherapy can improve the survival of patients with multiple brain metastases from non-small cell lung cancer treated by epidermal growth factor receptor-tyrosine kinase inhibitors[J]. Cancer Manag Res, 2020, 12:11333-11340.DOI:10.2147/ CMAR. S279096. [21] Saida Y, Watanabe S, Abe T, et al. Efficacy of EGFR-TKIs with or without upfront brain radiotherapy for EGFR-mutant NSCLC patients with central nervous system metastases[J]. Thoracic Cancer, 2019, 10(11):2106-2116.DOI:10.1111/1759-7714.13189. [22] Chen YS, Yang J, Li X, et al. First-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor alone or with whole-brain radiotherapy for brain metastases in patients with EGFR-mutated lung adenocarcinoma[J]. Cancer Sci. 2016, 107(12):1800-1805. DOI:10.1111/cas.13079. [23] Park S, Lee MH, Seong M, et al. A phase Ⅱ, multicenter, two cohort study of 160mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy[J]. Ann Oncol, 2020, 31(10):1397-1404.DOI:10.1016/j.annonc.2020.06.017. [24] Ohe Y, Imamura F, Nogami N, et al. Osimertinib versus standard-of-care EGFR-TKI as first-line treatment for EGFRm advanced NSCLC:FLAURA Japanese subset[J]. Jpn J Clin Oncol, 2019, 49(1):29-36.DOI:10.1093/jjco/hyy179. [25] Paget S. The distribution of secondary growths in cancer of the breast. 1889[J]. Cancer Metastasis Rev, 1989, 8(2):98-101. [26] 马齐襄,朱晓丹,胡凯文,等. 肿瘤转移的种子与土壤学说新认识[J]. 肿瘤防治研究,2015, 42(10):1049-1053.DOI:10.3971/ j.issn.1000-8578.2015.10.021. Ma QX, Zhu XD, Hu KW, et al. New thoughts upon seed an soil hypothesis of tumor metastasis[J]. Cancer Res Prev Treat, 2015, 42(10):1049-1053.DOI:10.3971/ j.issn.1000-8578.2015.10.021. [27] Wang G, Xu J, Qi Y, et al. Distribution of brain metastasis from lung cancer[J]. Cancer Manag Res, 2019, 11:9331-9338. DOI:10.2147/CMAR. S222920. [28] Lin CY, Chang CC, Su PL, et al. Brain MRI imaging characteristics predict treatment response and outcome in patients with de novo brain metastasis of EGFR-mutated NSCLC[J]. Medicine, 2019, 98(33):e16766.DOI:10.1097/MD. 0000000000016766. [29] Takano K, Kinoshita M, Takagaki M, et al. Different spatial distributions of brain metastases from lung cancer by histological subtype and mutation status of epidermal growth factor receptor[J]. Neuro-Oncol, 2016, 18(5):716-724.DOI:10.1093/neuonc/ nov266. [30] Mok TS, Y-L W, M-J A, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer[J]. N Engl J Med, 2017, 376(7):629-640.DOI:10.1056/NEJMoa 1612674. [31] Wu YL, Ahn MJ, Garassino MC, et al. CNS Efficacy of osimertinib in patients with T790M-positive advanced non-small-cell lung cancer:data from a randomized phase Ⅲ trial (AURA3)[J]. J Clin Oncol, 2018, 36(26):2702-2709. DOI:10.1200/JCO.2018.77.9363. [32] Subashi E, Cordero FJ, Halvorson KG, et al. Tumor location, but not H3.3K27M, significantly influences the blood-brain-barrier permeability in a genetic mouse model of pediatric high-grade glioma[J]. J Neurooncol, 2016, 126(2):243-251. DOI:10.1007/s11060-015-1969-9. [33] Das AK, Sato M, Story MD, et al. Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation[J]. Cancer Res, 2006, 66(19):9601-9608. DOI:10.1158/0008-5472. CAN-06-2627. [34] Anakura M, Nachankar A, Kobayashi D, et al. Radiosensitivity differences between EGFR mutant and wild-type lung cancer cells are larger at lower doses[J]. Int J Molecul Sci, 2019, 20(15):3635. DOI:10.3390/ijms20153635. [35] Xie B, Sun LY, Cheng YJ, et al. Epidermal growth factor receptor gene mutations in non-small-cell lung cancer cells are associated with increased radiosensitivity in vitro[J]. Cancer Manag Res, 2018, 10:3551-3560.DOI:10.2147/CMAR. S165831. [36] Lee CC, Lin CJ, Wu HM, et al. Epidermal growth factor receptor mutations:association with favorable local tumor control following Gamma Knife radiosurgery in patients with non–small cell lung cancer and brain metastases[J]. J Neurosurg, 2020, 133:313-320.DOI:10.3171/2019.4.JNS19446. [37] Arrieta O, Ramírez-Tirado LA, Caballé-Perez E, et al. Response rate of patients with baseline brain metastases from recently diagnosed non-small cell lung cancer receiving radiotherapy according to EGFR, ALK and KRAS mutation status[J]. Thorac Cancer, 2020, 11(4):1026-1037.DOI:10.1111/1759-7714.13359. [38] Wang D, Wang C, Wang L, et al. A comprehensive review in improving delivery of small-molecule chemotherapeutic agents overcoming the blood-brain/ brain tumor barriers for glioblastoma treatment[J]. Drug Deliv, 2019, 26(1):551-565. DOI:10.1080/10717544.2019.1616235. [39] Zeng YD, Liao H, Qin T, et al. Blood-brain barrier permeability of gefitinib in patients with brain metastases from non-small-cell lung cancer before and during whole brain radiation therapy[J]. Oncotarget, 2015, 6(10):8366-8376.DOI:10.18632/oncotarget.3187. [40] Du XJ, Pan SM, Lai SZ, et al. Upfront cranial radiotherapy ∶EGFR tyrosine kinase inhibitors alone for the treatment of brain metastases from non-small-cell lung cancer:a meta-analysis of 1465 patients[J]. Front Oncol, 2018, 8:603.DOI:10.3389/fonc.2018.00603. [41] Zhuang H, Shi S, Chang JY. Treatment modes for EGFR mutations in patients with brain metastases from non-small cell lung cancer:controversy, causes, and solutions[J]. Trans Lung Cancer Res, 2019, 8(4):524-531. DOI:10.21037/tlcr.2019. 07.03. [42] Yang RF, Yu B, Zhang RQ, et al. Bevacizumab and gefitinib enhanced whole-brain radiation therapy for brain metastases due to non-small-cell lung cancer[J]. Braz J Med Biol Res, 2017, 51(1):e6073.DOI:10.1590/1414-431X20176073. [43] Ke SB, Qiu H, Chen JM, et al. Therapeutic effect of first-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) combined with whole brain radiotherapy on patients with EGFR mutation-positive lung adenocarcinoma and brain metastases[J]. Curr Med Sci, 2018, 38(6):1062-1068. DOI:10.1007/s11596-018-1984-0. [44] Yang Z, Zhang Y, Li R, et al. Whole brain radiotherapy with and without concurrent erlotinib in nsclc with brain metastases:a multicentre, open-label, randomized, controlled phase 3 trial[J]. Neuro-Oncol, 2021, 10:1093.DOI:10.1093/neuonc/noaa281. [45] Sung SY, Lee SW, Kwak YK, et al. Intracranial control and survival outcome of tyrosine kinase inhibitor (TKI) alone versus TKI plus radiotherapy for brain metastasis of epidermal growth factor receptor-mutant non-small cell lung cancer[J]. J Neurooncol, 2018, 139(1):205-213.DOI:10.1007/s11060-018-2861-1. [46] Kim MY, Kang MK. EP-1361:upfront cranial radiotherapy for EGFR mutant non-small cell lung cancer with brain metastases[J]. Radiother Oncol, 2018, 127:S743.DOI:10.1016/S0167-8140(18)31670-0. [47] Fan Y, Xu Y, Gong L, et al. Effects of icotinib with and without radiation therapy on patients with EGFR mutant non-small cell lung cancer and brain metastases[J]. Sci Rep, 2017, 7:45193.DOI:10.1038/srep45193. [48] Magnuson WJ, Yeung JT, Guillod PD, et al. Impact of deferring radiotherapy in patients with EGFR-mutant NSCLC that develop brain metastases[J]. Int J Radiat Oncol Biol Phys, 2016, 95(2):673-679. DOI:10.1016/j.ijrobp.2016.01.037. [49] Magnuson WJ, Lester-Coll NH, Wu AJ, et al. Management of brain metastases in tyrosine kinase inhibitor-nave epidermal growth factor receptor-mutant non-small-cell lung cancer:a retrospective multi-institutional analysis[J]. J Clin Oncol, 2017, 35(10):1070-1077.DOI:10.1200/JCO.2016.69.7144. [50] Li C, Guo J, Zhao L, et al. Upfront whole brain radiotherapy for multiple brain metastases in patients with EGFR-mutant lung adenocarcinoma[J]. Cancer Manag Res, 2019, 11(1):3433-3443.DOI:10.2147/CMAR. S196881. [51] Jiang T, Su C, Li X, et al. EGFR TKIs plus WBRT demonstrated no survival benefit other than that of TKIs alone in patients with NSCLC and EGFR mutation and brain metastases[J]. J Thor Oncol, 2016, 11(10):1718-1728. DOI:10.1016/j.jtho.2016.05.013. [52] Teng F, Tsien CI, Lawrence TS, et al. Blood–tumor barrier opening changes in brain metastases from pre to one-month post radiation therapy[J]. Radiother Oncol, 2017, 125(1):89-93.DOI:10.1016/j.radonc.2017.08.006. [53] 刘桂梅,张新勇,田翠孟,等. 全脑放疗时间对EGFR突变非小细胞肺癌脑转移患者生存的影响[J]. 中国肺癌杂志, 2016, 19(8):501-507.DOI:10.3779/j.issn.1009-3419.2016.08.03. Liu GM, Zhang XY, Tian CM, et, al. Timing of whole brain radiotherapy on survival of patients with EGFR-mutated non-small cell lung cancer and brain metastases[J]. Chin J Lung Cancer, 2016, 19(8):501-507.DOI:10.3779/j. issn.1009-3419.2016.08.03.
2021, Vol. 30 
